A versatile genome-scale PCR-based pipeline for high-definition DNA FISH

ArticleinNature Methods 10(2) · December 2012with77 Reads
Impact Factor: 32.07 · DOI: 10.1038/nmeth.2306 · Source: PubMed

We developed a cost-effective genome-scale PCR-based method for high-definition DNA FISH (HD-FISH). We visualized gene loci with diffraction-limited resolution, chromosomes as spot clusters and single genes together with transcripts by combining HD-FISH with single-molecule RNA FISH. We provide a database of over 4.3 million primer pairs targeting the human and mouse genomes that is readily usable for rapid and flexible generation of probes.

    • "After deposition of a CTC containing sample on a suitable surface, upcoming multiplex fluorescent staining technologies in combination with fast fluorescent digital scanners are expected to facilitate CTC recognition among many white blood cells [30]. Upon marking of the location of CTCs on the scanned surface by appropriate scanner software, CTCs may in principle be selected by the software, to subsequently perform sophisticated in situ molecular assays to measure the number of specific mRNA molecules and specific genomic mutations on a single cell basis [19,20,313233. In case of a large cell-covered surface area, microfluidics approaches can be developed to perform for example a PCR assay in situ within single drops generated locally on the surface e.g., by electro-wetting [34]. "
    [Show abstract] [Hide abstract] ABSTRACT: Knowledge on cellular signal transduction pathways as drivers of cancer growth and metastasis has fuelled development of "targeted therapy" which "targets" aberrant oncogenic signal transduction pathways. These drugs require nearly invariably companion diagnostic tests to identify the tumor-driving pathway and the cause of the abnormal pathway activity in a tumor sample, both for therapy response prediction as well as for monitoring of therapy response and emerging secondary drug resistance. Obtaining sufficient tumor material for this analysis in the metastatic setting is a challenge, and circulating tumor cells (CTCs) may provide an attractive alternative to biopsy on the premise that they can be captured from blood and the companion diagnostic test results are correctly interpreted. We discuss novel companion diagnostic directions, including the challenges, to identify the tumor driving pathway in CTCs, which in combination with a digital pathology platform and algorithms to quantitatively interpret complex CTC diagnostic results may enable optimized therapy response prediction and monitoring. In contrast to CTC-based companion diagnostics, CTC enumeration is envisioned to be largely replaced by cell free tumor DNA measurements in blood for therapy response and recurrence monitoring. The recent emergence of novel in vitro human model systems in the form of cancer-on-a-chip may enable elucidation of some of the so far elusive characteristics of CTCs, and is expected to contribute to more efficient CTC capture and CTC-based diagnostics.
    Full-text · Article · Jun 2014 · Cancers
    0Comments 6Citations
    • "We performed imaging as described earlier (Bienko et al., 2013) using an inverted epi-fluorescence microscope (Nikon) equipped with a high-resolution charge-coupled device camera (Pixis, Princeton Intruments). Magnification of 1003 and 403 oil immersion, high-numerical-aperture Nikon objectives were used for cells and tissues, and purified RNA, respectively. "
    [Show abstract] [Hide abstract] ABSTRACT: Transcribed gene fusions are key biomarkers in many hematologic and solid tumors, often representing the primary oncogenic driver mutation. Here, we report an experimental and computational pipeline for detecting fusion transcripts using single-molecule RNA FISH and unbiased correlation analysis (FuseFISH). We constructed a genome-wide database of optimal oligonucleotide sequences, enabling quick design of FuseFISH probes against known and novel fusions. We implemented FuseFISH in cell lines, tissue sections, and purified RNA, reliably detecting one BCR-ABL1 positive in 10,000 negative cells. In 34 hematologic samples, we detected BCR-ABL1 transcripts with high specificity and sensitivity. Finally, we measured BCR-ABL1 expression heterogeneity and dynamics in single CML cells exposed to the kinase inhibitor Nilotinib. Our resource and methods are ideal for streamlined validation of fusions newly identified by next-generation sequencing, and they pave the way to studying the impact of fusion expression variability on clinical outcome.
    Full-text · Article · Dec 2013 · Cell Reports
    0Comments 7Citations
  • [Show abstract] [Hide abstract] ABSTRACT: A host of observations demonstrating the relationship between nuclear architecture and processes such as gene expression have led to a number of new technologies for interrogating chromosome positioning. Whereas some of these technologies reconstruct intermolecular interactions, others have enhanced our ability to visualize chromosomes in situ. Here, we describe an oligonucleotide- and PCR-based strategy for fluorescence in situ hybridization (FISH) and a bioinformatic platform that enables this technology to be extended to any organism whose genome has been sequenced. The oligonucleotide probes are renewable, highly efficient, and able to robustly label chromosomes in cell culture, fixed tissues, and metaphase spreads. Our method gives researchers precise control over the sequences they target and allows for single and multicolor imaging of regions ranging from tens of kilobases to megabases with the same basic protocol. We anticipate this technology will lead to an enhanced ability to visualize interphase and metaphase chromosomes.
    Full-text · Article · Dec 2012 · Proceedings of the National Academy of Sciences
    0Comments 40Citations
Show more